הכנסה תפעולית לפני ניכוי פחת: 23andMe (ME)

23andMe Holding Co. (ME) minimizes biotech risks by combining consumer DNA testing with drug discovery. The gross operating profit before depreciation and amortization trend on the GURU.Markets chart confirms this approach, where captures the current state of the parameter. The company is implementing cloud AI for precise genome analysis, leveraging its status as a recognized industry leader and its uncompromising protection of personal data for millions of loyal users.
23andMe (ME) - פילוחי מדדים ודוחות פיננסיים

Investors use this indicator for a real-time assessment of operational efficiency and cash generation rates. This metric measures daily EBITDA, which, in the operating profit summary, confirms the successful monetization of 23andMe Holding Co. (ME) genetic databases through pharmaceutical contracts and the development of paid subscription services.